Enveric Biosciences, Inc. (ENVB)
| Market Cap | 6.49M +86.9% |
| Revenue (ttm) | n/a |
| Net Income | -12.09M |
| EPS | -7.48 |
| Shares Out | 4.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,454 |
| Open | 1.410 |
| Previous Close | 1.430 |
| Day's Range | 1.410 - 1.540 |
| 52-Week Range | 1.170 - 13.250 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 17, 2026 |
About ENVB
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary... [Read more]
Financial Performance
Financial StatementsNews
Enveric Biosciences announces results from IND-enabling ADMET studies
Enveric Biosciences (ENVB) announced positive results from recently completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity, ADMET, studies for its lead non-halluc...
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric receives Notice of Allowance from USPTO for application for EVM401
Enveric Biosciences (ENVB) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for a patent application covering novel compounds within its…
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychi...
Enveric Biosciences reports new preclinical data on EB-003
Enveric Biosciences (ENVB) announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003. Preclinical testi...
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric ‘welcomes’ final FDA guidance for psychedelic drug development
Enveric Biosciences (ENVB) welcomed the U.S. Food and Drug Administration’s recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. “The ...
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences Announces Participation in 2026 BIO International Convention
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences initiates IND-enabling Genotoxicity studies of EB-003
Enveric Biosciences (ENVB) announced the Initiation of Investigational New Drug, IND,-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice...
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences reports preclinical results from analysis of EB-003
Enveric Biosciences (ENVB) announced “promising” results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further der...
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences reports Q1 EPS ($1.08) vs. ($14.58) last year
“Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics capable of addressing the significant unmet need in mental health,” said Jos...
Enveric Biosciences sees cash runway into 1Q27
“In April 2026, Enveric completed a private placement expected to generate gross proceeds of up to $13.9 million, including $5.0 million received at closing, and assuming full exercise of the…
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychi...
Enveric issued U.S. patent for methods of treating psychiatric disorders
Enveric Biosciences (ENVB) announced that the United States Patent and Trademark Office issued to Enveric US Patent No. 12,605,361, titled, “Carboxylated Psilocybin Derivatives and Methods of Using,” ...
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences highlights preclinical data for EB-003
Enveric Biosciences (ENVB) highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freez...
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences trading resumes
09:38 EDT Enveric Biosciences (ENVB) trading resumes